HIV cross-reactive antigens in breast and gynecological cancer (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


HIV cross-reactive antigens in breast and gynecological cancer (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 35:A2975 1994. Unique Identifier : AIDSLINE ICDB/95604660
Rakowicz-Szulczynska EM; McIntosh DG; Piao J; Smith M; Dept. of Obstetrics and Gynecology, Univ. of Nebraska Medical; Center, 600 South 42nd St., Omaha, NE 68198-3255

Abstract: We have identified a novel family of breast cancer- and gynecological cancer-associated antigens which cross-react in western blotting and are immunoprecipitated with a monoclonal antibody (MAb) developed against the variable loop of the human immunodeficiency virus (HIV-I) envelope protein gp120. Four HIV cross-reactive antigens are detected in breast cancer (p160/p80, p45 and p24) and three antigens (p120, p41, and p24) in gynecological cancer (ovarian, cervical, endometrial, vulvar), the molecular weights of which correspond to known HIV antigens. All cancer antigens exhibit plasma membrane/cytoplasmic localization, and p24 is also expressed in the chromatin. Antibodies produced by HIV-infected patients detect cancer antigens p80, p45/p41, and p24. HIV cross-reactive antigens, with the exception of p24, are neither detectable on normal epithelial cells nor in cancer of the gastrointestinal tract, lung cancer, and melanoma. We suggest that the novel antigens represent either the product(s) of an unknown retrovirus of homology to HIV, or the products of a cellular proto-oncogene(s). Antigen p160- and p120-mediated internalization of MAb leads to a growth-modulatory effect. 125I-labeled MAb exerts a cytotoxic effect due to the chromosomal damage caused by the radiation of 125I-MAb that becomes chromatin bound, and may represent a useful tool in cancer immunotherapy.
Keywords: Breast Neoplasms/*IMMUNOLOGY Female Genital Neoplasms, Female/*IMMUNOLOGY Human HIV Antigens/*ANALYSIS ABSTRACTKWDbreastneoplasms/KWDimmunologyfemalegenitalneoplasms,female/KWDimmunologyhumanhivantigens/KWDanalysisabstract
950330
M9530835

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .